Assay.Works and 2bind Partner to Expand Lead Discovery Services
Combining expertise in functional bioassays and molecular interaction studies with High Throughput Screening (HTS) capabilities creates a comprehensive service portfolio supporting Drug Discovery programs.
HTS is a well-established methodology for identifying new lead compounds for drug discovery and chemical biology. Molecular interaction studies are ideally suited to elucidate the molecular mechanism of hit compounds derived from HTS. A combination of HTS, high quality compound libraries, and an understanding of the mechanism of action facilitates the identification and prioritization of unique and tractable starting points for drug discovery programs.
The agreement gives Assay.Works access to 2bind's extensive experience with molecular interaction studies for hit identification, validation, and characterization. Biophysical assay technologies include MicroScale Thermophoresis (MST), nano-scale Differential Scanning Fluorimetry (nanoDSF), Biolayer Interferometry (BLI), and Isothermal Titration Calorimetry (ITC).
2bind's clients will benefit from Assay.Works' broad range of cell-based and biochemical assay capabilities combined with extensive experience in HTS and assay automation. 2bind gains access to 384-well format screening and nanoliter dispensing instrumentation, libraries totaling 150.000 small molecules and 97.000 siRNAs, and a portfolio of assay cell lines.
As part of the agreement, the companies share common laboratory and administrative premises at the BioPark Regensburg. The co-localization facilitates seamless interaction, scientific exchange, and efficiency gains via sharing infrastructure and laboratory equipment.
Dr. Ralf Schwandner, Assay.Works Founder and CEO, commented: "We are excited to partner with 2bind and offer our clients a suite of biophysical assays for hit and lead characterization. The molecular interaction technology perfectly complements our hit-to-lead workflow and the 2bind scientists share our collaborative mindset and approach to client programs. Not to forget, they are a fun team to work with."
Dr. Thomas Schubert, CEO, 2bind added: "You just have to grasp such excellent opportunities!
Dr. Ralf Schwandner
CEO, Assay.Works GmbH
Tel: +49 (941) 2000 1240
Dr. Thomas Schubert;
CEO, 2bind GmbH,
Tel: +49 (941) 2000 0890
Assay.Works is a contract research organization (CRO) providing research services to pharmaceutical/
Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.
Our service portfolio includes Assay Development, Cell Line Engineering and Production of Cellular Reagents, Bioactivity Assessments, Quantitative Biology Applications, and High-Throughput Screening (HTS).
2bind is a contract research organization (CRO) offering biophysical analytical services in early drug discovery to clients from biotech, pharma, and academic institutions in a fee-for-service business model.
Our mission is to give researchers, developers, and decision makers the power to accelerate and streamline their key research processes. Based on our four core technologies (MicroScale Thermophoresis, nanoDSF, Biolayer Interferometry, and Isothermal Titration Calorimetry)